102 related articles for article (PubMed ID: 10607740)
21. p53 Gene mutations in superficial bladder cancer.
Lorenzo Romero JG; Salinas Sánchez AS; Giménez Bachs JM; Sánchez Sánchez F; Escribano Martínez J; Hernández Millán IR; Segura Martín M; Virseda Rodríguez JA
Urol Int; 2004; 73(3):212-8. PubMed ID: 15539839
[TBL] [Abstract][Full Text] [Related]
22. Cigarette smoking and p53 mutations in lung cancer and bladder cancer.
Husgafvel-Pursiainen K; Kannio A
Environ Health Perspect; 1996 May; 104 Suppl 3(Suppl 3):553-6. PubMed ID: 8781382
[TBL] [Abstract][Full Text] [Related]
23. Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression.
Rieger KM; Little AF; Swart JM; Kastrinakis WV; Fitzgerald JM; Hess DT; Libertino JA; Summerhayes IC
Br J Cancer; 1995 Sep; 72(3):683-90. PubMed ID: 7669581
[TBL] [Abstract][Full Text] [Related]
24. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
26. Absence of point mutations at codon 17 of the mdm2 gene (serine 17) in human primary tumors.
Silva J; Silva JM; Dominguez G; Garcia JM; Rodriguez O; Garcia-Andrade C; Cuevas J; Provencio M; España P; Bonilla F
Mutat Res; 2000 Apr; 449(1-2):41-5. PubMed ID: 10751633
[TBL] [Abstract][Full Text] [Related]
27. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.
Wang YC; Lin RK; Tan YH; Chen JT; Chen CY; Wang YC
J Clin Oncol; 2005 Jan; 23(1):154-64. PubMed ID: 15625370
[TBL] [Abstract][Full Text] [Related]
28. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
29. P53 alterations in bladder tumors from arsenic and tobacco exposed patients.
Moore LE; Smith AH; Eng C; DeVries S; Kalman D; Bhargava V; Chew K; Ferreccio C; Rey OA; Hopenhayn C; Biggs ML; Bates MN; Waldman FM
Carcinogenesis; 2003 Nov; 24(11):1785-91. PubMed ID: 12919957
[TBL] [Abstract][Full Text] [Related]
30. Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder.
Friedrich MG; Riethdorf S; Erbersdobler A; Tiemer C; Schwaibold H; Sölter JK; Huland E; Riethdorf L; Conrad S; Hammerer PG; Huland H
Eur Urol; 2001 Feb; 39(2):159-66. PubMed ID: 11223675
[TBL] [Abstract][Full Text] [Related]
31. Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects.
Vet JA; Bringuier PP; Schaafsma HE; Witjes JA; Debruyne FM; Schalken JA
Lab Invest; 1995 Dec; 73(6):837-43. PubMed ID: 8558845
[TBL] [Abstract][Full Text] [Related]
32. Tobacco smoking, occupation, and p53 nuclear overexpression in early stage bladder cancer.
Zhang ZF; Sarkis AS; Cordon-Cardo C; Dalbagni G; Melamed J; Aprikian A; Pollack D; Sheinfeld J; Herr HW; Fair WR
Cancer Epidemiol Biomarkers Prev; 1994; 3(1):19-24. PubMed ID: 8118380
[TBL] [Abstract][Full Text] [Related]
33. p53 and ras mutations in Ewing's sarcoma.
Radig K; Schneider-Stock R; Röse I; Mittler U; Oda Y; Roessner A
Pathol Res Pract; 1998; 194(3):157-62. PubMed ID: 9587933
[TBL] [Abstract][Full Text] [Related]
34. p53 mutations in bladder carcinoma cell lines.
Cooper MJ; Haluschak JJ; Johnson D; Schwartz S; Morrison LJ; Lippa M; Hatzivassiliou G; Tan J
Oncol Res; 1994; 6(12):569-79. PubMed ID: 7787250
[TBL] [Abstract][Full Text] [Related]
35. Frequent mutations of the p53 gene and infrequent H- and K-ras mutations in urinary bladder carcinomas of NON/Shi mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine.
Yamamoto S; Masui T; Murai T; Mori S; Oohara T; Makino S; Fukushima S; Tatematsu M
Carcinogenesis; 1995 Oct; 16(10):2363-8. PubMed ID: 7586136
[TBL] [Abstract][Full Text] [Related]
36. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma.
Jahnson S; Karlsson MG
Cancer; 2000 Aug; 89(3):619-29. PubMed ID: 10931462
[TBL] [Abstract][Full Text] [Related]
37. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
38. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
[TBL] [Abstract][Full Text] [Related]
39. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer.
Habuchi T; Takahashi R; Yamada H; Ogawa O; Kakehi Y; Ogura K; Hamazaki S; Toguchida J; Ishizaki K; Fujita J
Cancer Res; 1993 Aug; 53(16):3795-9. PubMed ID: 8339293
[TBL] [Abstract][Full Text] [Related]
40. A hot spot for p53 mutation in transitional cell carcinoma of the bladder: clues to the etiology of bladder cancer.
Xu X; Stower MJ; Reid IN; Garner RC; Burns PA
Cancer Epidemiol Biomarkers Prev; 1997 Aug; 6(8):611-6. PubMed ID: 9264274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
